UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Intranasal lysine-aspirin administration decreases polyp volume in patients with aspirin-intolerant asthma

Ogata, N; Darby, Y; Scadding, G; (2007) Intranasal lysine-aspirin administration decreases polyp volume in patients with aspirin-intolerant asthma. Journal of Laryngology and Otology , 121 (12) 1156 - 1160. 10.1017/S0022215107000515. Green open access

[thumbnail of S0022215107000515.pdf]
Preview
PDF
S0022215107000515.pdf
Available under License : See the attached licence file.

Download (524kB)

Abstract

Introduction: Nasal polyposis associated with aspirin-intolerant asthma tends to be difficult to control, with frequent recurrences. We examined the effect of intranasal lysine-aspirin administration on resistant nasal polyps of asthmatic, aspirin-intolerant patients, when used in addition to routine therapy. Patients and methods: Thirteen patients with asthma and intolerance to aspirin were recruited. All but one had undergone numerous polypectomies and were uncontrolled on standard therapy with intranasal corticosteroids, leukotriene receptor antagonists and nasal douching. Aspirin treatment involved one drop (100 mu l) of 30 mg/ml lysine-aspirin solution to each nostril, initially daily, increased every two or three days up to a maximal of 18 drops (54 mg lysine-aspirin) a day. Nasal symptoms, nitric oxide level, nasal inspiratory peak flow rate, peak expiratory flow rate and nasendoscopic grading were assessed prior to therapy and three months later. We also compared the change in endoscopic polyp scores during three months of lysine-aspirin administration with the changes which had occurred during the three months prior to administration (during which time other therapies had been identical). Results: Nasal blockage symptoms tended to decrease; other nasal symptoms were unchanged. Significant changes were seen in nasal inspiratory peak flow rate (103.3 +/- 18.9 and 140.0 +/- 16.71/min before and after aspirin, respectively; p = 0.014), but not in peak expiratory flow rate (438.7 +/- 33.4 and 440.0 +/- 28.4 1/min before and after aspirin, respectively; p = 0.700). Nasal nitric oxide levels rose significantly (in both sides, p = 0.028). Expired chest nitric oxide levels did not change. Nasal polyp scores on nasendoscopic examination were significantly reduced (right side, p = 0.027; left side, p = 0.018). Compared with the preceding three months, adding intranasal lysine-aspirin application had the effect on decreasing nasal polyp volume (right side, p = 0.031; left side, p = 0.016). Conclusion: This open study suggests that intranasal lysine-aspirin administration reduces nasal polyp volume in aspirin-intolerant patients, without any adverse affect on concomitant asthma. This was a preliminary study and should be followed by a placebo-controlled, double-blind trial.

Type: Article
Title: Intranasal lysine-aspirin administration decreases polyp volume in patients with aspirin-intolerant asthma
Open access status: An open access version is available from UCL Discovery
DOI: 10.1017/S0022215107000515
Publisher version: http://dx.doi.org/10.1017/S0022215107000515
Language: English
Additional information: Copyright Cambridge University Press 2007
Keywords: Nasal polyp, Aspirin, Lysine-acetylsalicylate, Asthma, Nasal nitric-oxide, Sensitive rhinosinusitis, Desensitization, Inhibition, Acetylsalicylate
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Infection and Immunity
URI: https://discovery.ucl.ac.uk/id/eprint/1305623
Downloads since deposit
380Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item